Diabetes and Mortality in Men With Locally Advanced Prostate Cancer: RTOG 92-02 Editorial Comment

被引:0
|
作者
Smith, M. R. [1 ]
Bae, K. [1 ]
Efstathiou, J. A. [1 ]
Hanks, G. E. [1 ]
Pilepich, M. V. [1 ]
Sandler, H. M. [1 ]
Shipley, W. U. [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Hematol & Oncol, Boston, MA 02114 USA
来源
JOURNAL OF UROLOGY | 2009年 / 181卷 / 06期
关键词
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Diabetes is associated with lower risk of prostate cancer. Most men with diabetes are obese, and obesity is associated with greater prostate cancer mortality. Whether diabetes influences outcome is after prostate cancer diagnosis is unknown. Patients and Methods: We assessed the relationship between prevalent diabetes and mortality using data from Radiation Therapy Oncology Group Protocol 92-02, a large randomized trial of men (N = 1,554) treated with radiation therapy and short-term versus long-term adjuvant goserelin for locally advanced prostate cancer. Regression and proportional hazard models were performed to evaluate relationships between prevalent diabetes and all-cause mortality, prostate cancer mortality, and non-prostate cancer mortality. Covariates included age, race, tumor stage, Gleason score, prostate-specific antigen, weight, and treatment arm. Results: There were a total of 765 deaths; 210 (27%) were attributed to prostate cancer. In univariate analyses, prevalent diabetes was associated with greater all-cause mortality and non-prostate cancer mortality but not prostate cancer mortality. After controlling for other covariates, prevalent diabetes remained significantly associated with greater all-cause mortality and non-prostate cancer mortality (hazard ratio [HR] = 2.12; 95% CI, 1.69 to 2.66; P < .0001) but not prostate cancer mortality (HR = -0.80; 95% Cl, 0.51 to 1.25; P = .34). In contrast, weight was associated with greater prostate cancer mortality (HR = 1.77; 95% Cl, 1.22 to 2.55; P = .002) but not all-cause or non-prostate cancer mortality. Conclusion: Weight but not prevalent diabetes is associated with greater prostate cancer mortality in men receiving combined modality treatment for locally advanced disease. These observations suggest that the association between obesity and greater prostate cancer mortality is mediated by mechanism(s) other than the characteristic metabolic alterations of diabetes.
引用
收藏
页码:2533 / 2533
页数:1
相关论文
共 50 条
  • [1] Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02
    Smith, Matthew R.
    Bae, Kyounghwa
    Efstathiou, Jason A.
    Hanks, Gerald E.
    Pilepich, Miljenko V.
    Sandler, Howard M.
    Shipley, William U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4333 - 4339
  • [2] Diabetes and mortality in men with locally advanced prostate cancer: analyses of RTOG 92-02
    Smith, M. R.
    Kyounghwa, B.
    Efstathiou, J. A.
    Hanks, G. E.
    Pilepich, M. V.
    Sandler, H. M.
    Shipley, W. U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Diabetes and Cardiovascular Mortality in Men With Locally Advanced Prostate Cancer: Updated Analysis From RTOG 92-02
    Mak, K. S.
    Yan, Y.
    Smith, M. R.
    Hanks, G. E.
    Brereton, H. D.
    Bauman, G.
    Rosenthal, S. A.
    Zeitzer, K. L.
    Sandler, H. M.
    Efstathiou, J. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S94 - S94
  • [4] Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02
    Efstathiou, Jason A.
    Bae, Kyounghwa
    Shipley, William U.
    Hanks, Gerald E.
    Pilepich, Miljenko V.
    Sandler, Howard M.
    Smith, Matthew R.
    [J]. EUROPEAN UROLOGY, 2008, 54 (04) : 816 - 824
  • [5] The prognostic value of p16 expression in locally advanced prostate cancer: A study based on RTOG 92-02
    Chakravarti, A
    Desilvio, M
    Zhang, M
    Grignon, D
    Rosenthal, S
    Asbell, S
    Hanks, G
    Sandler, H
    Pollack, A
    Zhai, G
    Shipley, W
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S17 - S18
  • [6] Ten year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
    Hanks, G. E.
    Bae, K.
    Porter, A. T.
    Grignon, D.
    Brereton, H. D.
    Venkatesan, V. M.
    Horwitz, E. M.
    Lawton, C.
    Sandler, H. M.
    Shipley, W. U.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S13 - S13
  • [7] Cox-2 overexpression predicts prostate cancer outcome: An analysis of RTOG 92-02
    Khor, L.
    Bae, K.
    Hammond, M. E.
    Pollack, A.
    Venkatesan, V.
    Rosenthal, S. A.
    Sandler, H.
    Hanks, G. E.
    Shipley, W. U.
    Dicker, A. P.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S202 - S202
  • [8] Bcl-2 and bax predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on RTOG 92-02
    Pollack, A.
    Moughan, J.
    Khor, L.
    Al-Saleem, T.
    Hammond, M. E.
    Venkatesan, V.
    Rosenthal, S. A.
    Hanks, G. E.
    Shipley, W.
    Sandler, H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S201 - S201
  • [9] Bcl-2 and Bax are determinants of prostate cancer outcome in men treated with androgen deprivation and radiotherapy on RTOG 92-02
    Pollack, A.
    Moughan, J.
    Khor, L.-Y
    Al-Saleem, T.
    Hammond, M. E.
    Venkatesan, V.
    Rosenthal, S.
    Hanks, G. E.
    Shipley, W.
    Sandler, H.
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2007, 22 (01): : 79 - 79
  • [10] MDM2 and Ki-67 Predict for Distant Metastasis and Mortality in Men Treated With Radiotherapy and Androgen Deprivation for Prostate Cancer: RTOG 92-02
    Khor, Li-Yan
    Bae, Kyounghwa
    Paulus, Rebecca
    Al-Saleem, Tahseen
    Hammond, M. Elizabeth
    Grignon, David J.
    Che, Mingxin
    Venkatesan, Varagur
    Byhardt, Roger W.
    Rotman, Marvin
    Hanks, Gerald E.
    Sandler, Howard M.
    Pollack, Alan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3177 - 3184